Evidence map›Paper›PMID 29255378›Full record

ArticleCancer cell international2017

The human, F-actin-based cytoskeleton as a mutagen sensor.

Nicolette M Clark, Carlos A Garcia Galindo, Vandan K Patel, Michele L Parry, Rebecca J Stoll, John M Yavorski, Elizabeth P Pinkason, Edna M Johnson, Chelsea M Walker, Joseph Johnson and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Nicolette M ClarkDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Carlos A Garcia GalindoDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Vandan K PatelDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Michele L ParryDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Rebecca J StollDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
John M YavorskiDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Elizabeth P PinkasonDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Edna M JohnsonDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Chelsea M WalkerDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.
Joseph JohnsonAnalytical Microscopy Core Facility, Moffitt Cancer Center and Research Institute, Tampa, FL USA.
Wade J SextonDepartment of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL USA.
Domenico CoppolaDepartment of Pathology, Moffitt Cancer Center and Research Institute, Tampa, FL USA.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Bruce B. Downs Bd., Tampa, FL 12901 USA.ORCID 0000-0003-1664-0996
University of South Florida · USMoffitt Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

backgroundForty years ago the actin cytoskeleton was determined to be disrupted in fibroblasts from persons with DNA repair-defective, hereditary colon cancer, with no clear connection between the cytoskeleton and DNA repair defects at that time. Recently, the large number of sequenced genomes has indicated that mammalian mutagenesis has a large stochastic component. As a result, large coding regions are large mutagen targets. Cytoskeletal protein-related coding regions (CPCRs), including extra-cellular matrix proteins, are among the largest coding regions in the genome and are indeed very commonly mutated in cancer.

methodsTo determine whether mutagen sensitivity of the actin cytoskeleton could be assessed experimentally, we treated tissue culture cells with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and quantified overall cytoskeleton integrity with rhodamine-phalloidin stains for F-actin.

resultsThe above approach indicated cytoskeletal degradation with increasing mutagen exposure, consistent with increased mutagenesis of CPCRs in TCGA, smoker samples, where overall mutation rates correlate with CPCR mutation rates (R

conclusionDetermination of cytoskeletal integrity may provide the opportunity to assess mutation burdens in nonclonal cell populations, such as in intact tissues, where DNA sequencing for heterogeneous mutation burdens can be challenging.

Indexed as

Chemotherapy sequelaeCytoskeletonMutation frequencySmoking mutations

Identifiers

PMID29255378
PMCPMC5727871
OpenAlexW2771970560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.